R&D programs

OGD2 Pharma develops a humanized monoclonal antibody (OGD201) and companion diagnostic tools to select patients eligible to anti-O-acetylated-GD2 therapy and monitor treatment efficacy.

OGD2 Pharma also collaborates with various academic and industrial partners to explore the potential of new generation of immunotherapies such as CAR-T and CAR-NK cells targeting O-acetylated-GD2 in cancer therapy.

In construction

Leave a Reply